Kailera Therapeutics believes it can stand out in a crowded and competitive market for obesity medicines. Global clinical trials underway could help build the case for differentiation, and the company now has $625 million in IPO cash to support its pipeline of injectable and oral drugs through key data readouts.
Investors are apparently persuaded by Kailera’s prospects. Strong investor interest enabled Kailera to boost the deal size by adding nearly six million more shares than it initially planned to offer. Late Thursday, the Waltham, Massachusetts-based company priced 39 million shares at $16 each, which was the top of the price range it set in preliminary financial terms. Kailera’s shares will trade on the Nasdaq under the stock symbol “KLRA.”
The most advanced Kailera program is ribupatide, a peptide engineered to activate the GLP-1 and GIP receptors. Those are the same targets as Eli Lilly’s Zepbound, but Kailera contends its once-weekly injectable drug has greater binding affinity to its targets and a longer half-life that enables better drug exposure in the body through the full weekly dosing period. Three global Phase 3 tests of ribupatide are underway; preliminary data expected in 2028.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Kailera is also developing an oral version of ribupatide, KAI-9531. The oral obesity market is growing quickly following FDA approvals for daily pills from Eli Lilly and Novo Nordisk, both designed to activate the GLP-1 receptor. In addition to hitting two targets, Kailera contends its pill can stand apart with better tolerability. In the filing, Kailera said global Phase 3 tests of oral ribupatide could begin in the first half of 2027.
Competitive weight loss with better tolerability are also goals for KAI-7535, Kailera’s GLP-1 receptor-targeting pill. Like Lilly’s Foundayo, KAI-7535 is an oral small molecule that does not have the same dosing restrictions as Novo Nordisk’s Wegovy pill, an oral peptide. Kailera said preliminary results from a Phase 2 test of its oral GLP-1 drug are expected in 2027. By developing both injectable and oral obesity drugs, Kailera said it can address a broader range of patients, including those with high body mass indexes (BMIs) that require medication with a stronger effect than what’s offered by currently available products.
“We believe that injectable treatments will remain foundational for patients needing significant weight reduction,” Kailera said in the filing. “Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs.”
Kailera’s IPO comes less than two years after the biotech launched with four in-licensed metabolic disorder drugs supported by $400 million in Series A financing. Last October, Kailera closed a $600 million Series B round.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
In the IPO filing, Kailera reported its cash and marketable securities totaled $652 million as of the end of 2025. That capital combined with the IPO proceeds will support clinical development of the pipeline: $625 million for global Phase 3 tests of injectable ribupatide; $150 million to advance oral ribupatide to Phase 3; and $50 million to take GLP-1 pill KAI-7535 through the completion of a planned Phase 2 study. Kailera said it expects its capital will last into the second quarter of 2028.
Alamar’s IPO Will Finance Its Plans in Proteomics
Alamar Biosciences raised $191.3 million to grow the company, a maker and seller of instruments used in proteomics, the large-scale analysis of entire sets of proteins. The company’s products are based on a proprietary technology called Nucleic Acid Linked Immuno-Sandwich Assay, or NULISA for short. Alamar’s customers include universities, biopharmaceutical companies, and contract research organizations.
Fremont, California-based Alamar claims NULISA improves the signal-to-noise ratio compared to other proteomics technologies. Competitors include Quanterix and Olink, a Thermo Fisher Scientific subsidiary. The $74.2 million in revenue Alamar reported for 2025 is nearly triple the company’s revenue for the prior year. But Alamar is not yet profitable, posting a $29.8 million net loss last year.
“We expect that our losses will continue in the near term as we continue to invest significantly in research and development to enhance our NULISA technology, expand our NULISA assay menu and enhance our software offerings, expand our manufacturing capabilities, and build out our commercialization team and footprint,” Alamar said in its IPO filing.
Alamar offered 11.25 million shares at $17 apiece, which was the top end of the $15 to $17 price range the company set in preliminary IPO terms. The company’s shares will trade on the Nasdaq under the stock symbol “ALMR.”
More Biotechs Join the IPO Queue
Two more clinical-stage biotech companies revealed their plans to join the public markets. Seaport Therapeutics and Hemab Therapeutics recently filed IPO paperwork with the Securities and Exchange Commission.
Boston-based Seaport spun out of PureTech Health in 2024 with a platform technology that leverages the lymphatic system to make more of a drug’s active pharmaceutical ingredient available in the body to provide a therapeutic effect. Lead drug candidate SPT-300 is in Phase 2b testing for major depressive disorder; preliminary data are expected in the first half of 2027, according to the filing. Seaport has applied for a Nasdaq listing under the stock symbol “SPTX.”
Meanwhile, Hemab Therapeutics is eyeing a public listing to support its pipeline of drugs for blood clotting disorders. The Cambridge, Massachusetts-based company’s lead program is sutacimig (formerly HMB-001), a bispecific antibody currently in Phase 1/2 development for prophylactic treatment of Glanzmann thrombasthenia, a rare inherited disorder affecting platelets. Hemab expects to begin Phase 3 testing in this indication in the second half of the year, according to the filing. Sutacimig drug is also in Phase 2 testing for prophylactic treatment of deficiency of the clotting protein Factor VII. Hemab has applied for a Nasdaq listing under the stock symbol “COAG.”
Photo by Getty Images